Cancer Research Technology
Log in Register
Menu

3LL NRAS KO #63 cell line
RECENTLY UPDATED

Invented by Prof Julian Downward from Francis Crick Institute
Invented at The Francis Crick Institute

Info

Catalogue Number 157771
Parental Line 3LL aka LL/2 (LLC1) likely origin - please note genetic divergence in relevance information
Host Mouse
Tissue Lung
Model Knock-Out
Relevance Murine Lewis Lung Adenocarcinoma engineered cell line with NRAS knocked out using CRISPR-Cas9. Please note: The authors have established (by DNA sequencing) that these cells are homozygous for the KRAS-G12C & NRAS-Q61H mutations which is not the case for the parent 3LL ATCC line. It is assumed both mutant NRAS and KRAS in 3LL cells drive RAS pathway activation. By knocking out NRAS a tumourigenic cell line with a stronger dependency on KRAS-G12C was generated. Model cell line for study of the effect of KRAS-G12C inhibitors on oncogenic cells.
Research Area Cancer, Cell Cycle, Cell Signaling & Signal Transduction
Growth/Phenotype Keywords Semi-adherent
Recommended Growing Conditions RPMI+10%FCS+1%PS
Notes CRISPR edited 3LL cells.

Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.

This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Molina-Arcas et al. 2019. Sci Transl Med. 11(510):. PMID: 31534020.


Add a reference

References: 1 entry

Molina-Arcas et al. 2019. Sci Transl Med. 11(510):. PMID: 31534020.


Add a reference